Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 25, 2015 12:44 PM ET


Company Overview of MacroGenics, Inc.

Company Overview

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate product candidates and enter into various strategic collaborations with global pharmaceutical and biotechnology companies. Its product candidates include Margetuximab, a monoclonal antibody that targets human ep...

9640 Medical Center Drive

Rockville, MD 20850

United States

Founded in 2000

211 Employees





Key Executives for MacroGenics, Inc.

Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $466.5K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Age: 47
Total Annual Compensation: $313.8K
Senior Vice President of Research
Age: 60
Total Annual Compensation: $328.0K
Senior Vice President and General Counsel
Age: 41
Total Annual Compensation: $228.9K
Senior Vice President of Clinical Development
Age: 52
Total Annual Compensation: $148.6K
Compensation as of Fiscal Year 2014.

MacroGenics, Inc. Key Developments

MacroGenics, Inc. Presents Pre-Clinical Data on its Multivalent DR5 DART at the American Association for Cancer Research Annual Meeting

MacroGenics, Inc. announced the presentation of pre-clinical data for Dual-Affinity Re-Targeting (DART) molecules that target DR5 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. In addition, MacroGenics' collaboration partner, Pfizer Inc., presented pre-clinical data on a DART molecule that simultaneously targets P-cadherin and CD3. Ligation of DR5 with its cognate ligand TRAIL or agonistic monoclonal antibodies elicits a pro-apoptotic signal on cancer cells, leading to programmed cell death. DR5 monoclonal antibodies selected from MacroGenics' discovery platform based on favorable normal/tumor binding properties were incorporated into multivalent DARTs. The efficacy of the DR5 DART molecules in mediating cancer cell cytotoxicity is 10-100 fold enhanced compared to that of TRAIL and previously described agonistic DR5-targeted monoclonal antibodies. Based on their enhanced potency and selectivity, DR5-targeting DARTs represent a new class of therapeutics that may overcome limitations of existing DR5-targeted therapeutics. The pre-clinical data support the use of DR5-engaging DARTs to exploit this apoptotic pathway in multiple cancer types.

MacroGenics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:00 AM

MacroGenics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Scott Koenig, Chief Executive Officer, President and Director.

MacroGenics Begins Phase 1 Study of MGD010 for Treatment of Autoimmune Disorders

MacroGenics has begun its Phase 1 study with MGD010, the company's first Dual-Affinity Re-Targeting molecule being developed for patients with autoimmune disorders. This Phase 1 clinical trial is a first-in-human, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MGD010 in healthy subjects. MGD010 is a bi-specific molecule that simultaneously targets CD32B and CD79B, two B-cell surface proteins, for the treatment of autoimmune disorders. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells.

Similar Private Companies By Industry

Company Name Region
Omniome, Inc. United States
Biotic Laboratories, Inc. United States
Inhibitex, Inc. United States
Phage Pharmaceuticals, Inc. United States
BioCarta LLC United States

Recent Private Companies Transactions

Private Placement
December 19, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MacroGenics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at